M
Matthew C. Foster
Researcher at University of North Carolina at Chapel Hill
Publications - 89
Citations - 1649
Matthew C. Foster is an academic researcher from University of North Carolina at Chapel Hill. The author has contributed to research in topics: Myeloid leukemia & Medicine. The author has an hindex of 16, co-authored 72 publications receiving 1079 citations.
Papers
More filters
Journal ArticleDOI
A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403.
Wendy Stock,Selina M. Luger,Anjali S. Advani,Jun Yin,Richard C. Harvey,Charles G. Mullighan,Cheryl L. Willman,Noreen Fulton,Kristina Laumann,Greg Malnassy,Elisabeth Paietta,Edy Parker,Susan Geyer,Krzysztof Mrózek,Clara D. Bloomfield,Ben L. Sanford,Guido Marcucci,Michaela Liedtke,David F. Claxton,Matthew C. Foster,Jeffrey A. Bogart,John C. Grecula,Frederick R. Appelbaum,Harry P. Erba,Mark R. Litzow,Martin S. Tallman,Richard Stone,Richard A. Larson +27 more
TL;DR: Use of a pediatric regimen for AYA patients with newly diagnosed ALL up to age 40 years was feasible and effective, resulting in improved survival rates compared with historical controls, and CALGB 10403 can be considered a new treatment standard upon which to build for improving survival for AYAs with ALL.
Journal ArticleDOI
Deregulation of DUX4 and ERG in acute lymphoblastic leukemia
Jinghui Zhang,Kelly McCastlain,Hiroki Yoshihara,Beisi Xu,Yunchao Chang,Michelle L. Churchman,Gang Wu,Yongjin Li,Lei Wei,Ilaria Iacobucci,Yu Liu,Chunxu Qu,Ji Wen,Michael N. Edmonson,Debbie Payne-Turner,Kerstin B. Kaufmann,Shin-ichiro Takayanagi,Shin-ichiro Takayanagi,Erno Wienholds,Esmé Waanders,Esmé Waanders,Panagiotis Ntziachristos,Sofia Bakogianni,Jingjing Wang,Iannis Aifantis,Iannis Aifantis,Kathryn G. Roberts,Jing Ma,Guangchun Song,John Easton,Heather L. Mulder,Xiang Chen,Scott Newman,Xiaotu Ma,Michael Rusch,Pankaj Gupta,Kristy Boggs,Bhavin Vadodaria,James Dalton,Yanling Liu,Marcus L Valentine,Li Ding,Charles Lu,Robert S. Fulton,Lucinda Fulton,Yashodhan Tabib,Kerri Ochoa,Meenakshi Devidas,Deqing Pei,Cheng Cheng,Jun J. Yang,William E. Evans,Mary V. Relling,Ching-Hon Pui,Sima Jeha,Richard C. Harvey,I-Ming L. Chen,Cheryl L. Willman,Guido Marcucci,Clara D. Bloomfield,Jessica Kohlschmidt,Krzysztof Mrózek,Elisabeth Paietta,Martin S. Tallman,Wendy Stock,Matthew C. Foster,Janis Racevskis,Jacob M. Rowe,Selina M. Luger,Steven M. Kornblau,Sheila A. Shurtleff,Susana C. Raimondi,Elaine R. Mardis,Richard K. Wilson,John E. Dick,Stephen P. Hunger,Mignon L. Loh,James R. Downing,Charles G. Mullighan +78 more
TL;DR: A unique paradigm of transcription factor deregulation in leukemia is illustrated in which DUX4 deregulation results in loss of function of ERG, either by deletion or induced expression of an isoform that is a dominant-negative inhibitor of wild-type ERG function.
Journal ArticleDOI
Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia
Geoffrey L. Uy,Ibrahim Aldoss,Matthew C. Foster,Peter H. Sayre,Matthew J. Wieduwilt,Anjali S. Advani,John E. Godwin,Martha Arellano,Kendra Sweet,Ashkan Emadi,Farhad Ravandi,Harry P. Erba,Michael Byrne,Laura C. Michaelis,Max S. Topp,Norbert Vey,Fabio Ciceri,Matteo Carrabba,Stefania Paolini,Gerwin Huls,Mojca Jongen-Lavrencic,Martin Wermke,Patrice Chevallier,Emmanuel Gyan,Christian Recher,Patrick J. Stiff,Kristen Pettit,Bob Löwenberg,Sarah E. Church,Erica K. Anderson,Jayakumar Vadakekolathu,Marianne Santaguida,Michael P. Rettig,John Muth,Teia Curtis,Erin Fehr,Kuo Guo,Jian Zhao,Ouiam Bakkacha,Kenneth Jacobs,Kathy M. Tran,Patrick Kaminker,Maya Kostova,Ezio Bonvini,Roland B. Walter,Jan K Davidson-Moncada,Sergio Rutella,John F. DiPersio +47 more
TL;DR: Flotetuzumab represents an innovative experimental approach associated with acceptable safety and encouraging evidence of activity in PIF/ER AML patients and shows an association between an immune-infiltrated tumor microenvironment and resistance to cytarabine-based chemotherapy but responsiveness to flotetzumab.
Journal ArticleDOI
Favorable Outcomes for Older Adolescents and Young Adults (AYA) with Acute Lymphoblastic Leukemia (ALL): Early Results of U.S. Intergroup Trial C10403
Wendy Stock,Selina M. Luger,Anjali S. Advani,Susan Geyer,Susan Geyer,Richard C. Harvey,Charles G. Mullighan,Cheryl L. Willman,Greg Malnassy,Edy Parker,Kristina Laumann,Ben L. Sanford,Guido Marcucci,Elisabeth Paietta,Michaela Liedtke,David F. Claxton,Matthew C. Foster,Frederick R. Appelbaum,Harry P. Erba,Mark R. Litzow,Martin S. Tallman,Richard Stone,Richard A. Larson,Richard A. Larson +23 more
TL;DR: The purpose of C10403, a large prospective US intergroup trial, was to evaluate the feasibility and effectiveness of treating AYA ALL pts using the standard arm of the successful Children's Oncology Group regimen, and the results allow rejection of the null hypothesis.
Journal ArticleDOI
Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia.
Joshua F. Zeidner,Matthew C. Foster,Amanda L. Blackford,Mark R. Litzow,Lawrence E. Morris,Stephen A. Strickland,Jeffrey E. Lancet,Prithviraj Bose,M. Yair Levy,Raoul Tibes,Ivana Gojo,Christopher D. Gocke,Gary L. Rosner,Richard F. Little,John Wright,L. Austin Doyle,B. Douglas Smith,Judith E. Karp +17 more
TL;DR: Results substantiate the efficacy of FLAM induction in newly diagnosed AML and show no significant differences in overall survival and event-free survival in both arms but post-induction strategies were not standardized.